AmplifAI Health

Amplifai Health (amplifAI health) develops AI-powered thermal imaging for diabetic foot screening. Its product, TFscan, captures thermographic scans of a patient's feet with a portable thermal camera, runs automated analysis to detect abnormalities and risk, and tracks patient trends over time through dashboards and reports. The output includes explainable reports and a clinically aligned risk score based on IWGDF guidelines, intended as clinical decision support so care teams can intervene before complications develop.

The company positions the product around the burden of diabetic foot disease, citing figures such as one in four diabetic patients developing foot complications, a diabetes-related amputation every 20 seconds globally, roughly a third of diabetes costs attributable to foot complications, and a global burden exceeding $100 billion. The platform is deployed on secure, HIPAA-compliant managed tablets with Wi-Fi, LTE, offline mode and remote support, and is described as HL7 compatible for integration with EMR, EHR and hospital systems. An analytics dashboard supports population-level risk trend visualization across demographics.

The company also applies its thermographic technology beyond diabetic foot care, including vascular age analysis with Healthspan Digital and, reported in 2026, sports recovery applications.

Business model

Amplifai Health supplies its TFscan software as a medical device to hospitals, clinics and home-care providers, paired with managed portable tablets and thermal cameras deployed at the point of care. The platform is built for integration with existing clinical systems (HL7 compatibility with EMR/EHR and hospital infrastructure) and adds an analytics dashboard layer for population health reporting. Distribution runs through clinical partnerships and public-sector procurement channels, including registration with NUPCO in Saudi Arabia.